Why the study?
The study was conducted to understand current dyslipidemia diagnosis and treatment patterns in Turkey and identify unmet needs in achieving effective LDL-C targets.
A Delphi panel of Turkish cardiologists identified significant gaps in dyslipidemia management, particularly the underutilization of combination lipid-lowering therapies in high-risk patients, leading to poor LDL-C target attainment.
Suboptimal LDL-C management persists in most very high-risk patients; leaves open the need for implementation studies to close treatment gaps.
This study evaluated the management of dyslipidemia in Turkey with the goal of understanding current diagnosis and treatment patterns, as well as identifying unmet needs in achieving effective low-density lipoprotein cholesterol (LDL-C) targets. Using a Delphi panel consisting of nine expert cardiologists, the study reveals key gaps in dyslipidemia management, particularly in the underutilization of combination therapies, such as statins and PCSK9 inhibitors, which are crucial for achieving LDL-C targets in high-risk patients. The findings indicate that while many patients with very high cardiovascular risk are diagnosed, a significant proportion do not receive optimal treatment to reach LDL-C levels recommended by European guidelines. Addressing these gaps could lead to more effective management of dyslipidemia and reduce the burden of cardiovascular disease in Turkey. The study's insights provide critical recommendations for clinicians and policymakers to improve clinical practice and health outcomes through more aggressive lipid-lowering strategies.
No takes yet. Share an insight, caveat, or question.
Si̇nan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: